Principal Investigator Adam Chlipala
The pharmaceutical industry is under growing pressure from patent expirations of major drugs, cost-constrained health care systems, and a demanding regulatory environment. A focus for the industry is to tackle these challenges while increasing the output and quality of cost-effective, new medicines without incurring unsustainable R&D cost. Through new technology and new approaches there is an aspiration to make such improvements while also bringing ever-improved therapeutics to patients faster. In this conference, we will lay out many of the challenges the industry is facing and explore potential solutions coming from academic research and startup endeavors, from early discovery through manufacturing technologies, to clinical studies and beyond.
Principal Investigator Jeffrey Karp
Principal Investigator Richard Temkin
The pharmaceutical industry has experienced an extraordinary rise in the generation and use of enormous datasets. Nevertheless, there remain great challenges on this front regarding everything from target identification to understanding the performance of marketed products. In the context of this broad impact, we have assembled a group of leading researchers and executives from the MIT-connected community who will address questions of discovery, data integration, and system perturbation analysis, including use of artificial intelligence and machine learning techniques. What is the impact of current developments on high-throughput profiling, computational biology, and validation of gene targets? How do these developments impact the use of chemical libraries, drug-delivery systems, and patient-facing objectives? These are the types of questions that will be addressed in this exciting panel discussion.